Vedolizumab trough concentrations and clinical and endoscopic outcomes in inflammatory bowel disease: a systematic review and meta-analysis.
BACKGROUND AND AIMS The role of therapeutic drug monitoring (TDM) in optimizing vedolizumab (VDZ) therapy for Crohn's disease (CD) and ulcerative colitis (UC) remains unclear. Prior evidence was limited by small sample size and heterogeneous endpoints. We synthesized the available evidence on the association of VDZ tro...